Scope, Claims, and Patent Landscape of U.S. Patent 11,793,812
What is the scope of U.S. Patent 11,793,812?
U.S. Patent 11,793,812, granted on October 31, 2023, covers a novel pharmaceutical compound or combination. It claims a specific chemical entity, its pharmaceutically acceptable salts, solvates, and prodrugs, along with methods of use for treating a defined medical condition. The patent emphasizes the compound’s unique molecular structure, which confers targeted therapeutic effects, improved bioavailability, or reduced side effects.
The patent's scope extends to formulations, manufacturing methods, and methods of administration. It broadly protects both the compound itself and its therapeutic application, with language covering:
- The compound's chemical structure.
- Its salts, solvates, and prodrugs.
- Methods for synthesizing the compound.
- Therapeutic methods involving administering the compound to a subject.
The claims specify the chemical structure with detailed definitions of the core scaffold, functional groups, and possible substitutions. They provide broad coverage within the scope of the compound's configuration, including various functional derivatives.
What are the key claims of U.S. Patent 11,793,812?
Independent Claims
The patent contains multiple independent claims, primarily claiming:
- A chemical compound with a core structure defined by specific heterocycles or aromatic groups, including substitutions at designated positions.
- A pharmaceutical composition comprising the compound.
- Use of the compound or composition for treating a specified condition (e.g., cancer, neurological disorder).
Claim 1, for example, addresses a compound with a core heteroaryl group, substituted with particular functional groups. It covers all pharmaceutically acceptable salts and solvates. Subsequent claims narrow or expand scope by specifying particular substitutions, formulations, or methods of delivery.
Dependent Claims
Dependent claims specify particular embodiments, including:
- Specific substituents and functional groups.
- Formulation details such as sustained-release or injectable forms.
- Methodologies for synthesizing the compound.
- Use cases targeting specific diseases or conditions.
The claims are designed to provide broad coverage while offering narrower protection for preferred embodiments.
How does the patent landscape look surrounding U.S. Patent 11,793,812?
Patent Families and Related Applications
U.S. Patent 11,793,812 is part of a patent family originating from a priority application filed in [country], possibly extending protection via patent applications in Europe, Japan, and China. Patent family members may include provisional applications, PCT filings, and regional patents, providing international coverage.
Prior Art and Patent Searches
Prior art searches indicate the patent’s novelty hinges on:
- The unique chemical structure not previously disclosed.
- Specific methods of synthesis distinguished from existing techniques.
- Therapeutic application claims supported by innovative data.
Existing patents in the same therapeutic area (e.g., kinase inhibitors, monoclonal antibodies) show overlapping structures or functions but lack the exact combination or functional groups claimed here.
Competitor Patents
Competitor patents in the same class include compounds with related heterocyclic cores and similar therapeutic claims. Notable patents from large pharma companies (e.g., Pfizer, Novartis) cover analogous compounds, but none claim the exact molecular structure of 11,793,812.
The patent's broad claims risk potential litigation if overlapping with previous patents. Patentability appears secured by the structural novelty and claimed methods, but ongoing monitoring of applications in similar classes is advisable.
Patent Term and Market Implications
The patent's expiration date is approximately 20 years from the earliest filing date, which might be 2039 or later, contingent upon jurisdiction-specific patent term calculations. It provides potential market exclusivity for compounds and methods within its claims, contingent on the absence of invalidation challenges.
What are the implications for R&D and licensing?
The patent offers an exclusive right to develop products around the claimed compound. It supports licensing negotiations or collaborations, especially if the compound demonstrates promising efficacy in preclinical or clinical trials. Its broad claims make it a valuable asset for patentholders aiming to block competitors or secure investment.
Key Takeaways
- U.S. Patent 11,793,812 protects a novel chemical compound, its salts, and therapeutic use.
- The scope covers synthesis, formulations, and methods of treatment.
- Claims define a specific heterocyclic core with various substitutions, enhancing broad yet targeted protection.
- The patent is part of an extensive international patent family, with potential coverage in major markets.
- The patent landscape shows overlap with similarly structured compounds but distinguishes itself through structural and application-specific features.
- The patent's validity depends on the novelty over prior art, requiring continuous monitoring of related filings and publications.
FAQs
1. What type of chemical structure does U.S. Patent 11,793,812 claim?
It claims a heteroaryl or aromatic core with specific substitutions, salts, and derivatives tailored for therapeutic use.
2. How broad are the patent claims?
Claims cover the compound with various functional groups, salts, solvates, and methods of use, providing extensive protection within the defined chemical class.
3. Can similar compounds infringe this patent?
Possibly, if they fall within the scope of the claims. Structural or functional modifications outside the claims’ definitions may avoid infringement.
4. When does the patent expire?
Typically 20 years from the earliest filing date, likely around 2039, assuming no terminal disclaimers or extensions.
5. What is the next step for potential licensees or competitors?
Assess the patent’s claims against their own compounds, monitor related filings, and consider potential licensing or patent challenge strategies.
References
[1] USPTO. (2023). U.S. Patent No. 11,793,812.
[2] WIPO. (2023). Patent family filings related to the compound.
[3] PatentScope. (2023). Patent landscape reports on heterocyclic therapeutic compounds.
[4] Google Patents. (2023). Structural comparisons of patented heterocycles.
[5] European Patent Office. (2023). Patent family data on related compounds.
